Showing 1 - 15 results of 15 for search '"НОВАЯ КОРОНОВИРУСНАЯ ИНФЕКЦИЯ"', query time: 0.58s Refine Results
  1. 1
  2. 2
  3. 3
    Academic Journal

    Source: Сборник статей

    File Description: application/pdf

    Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; http://elib.usma.ru/handle/usma/13963

  4. 4
    Academic Journal

    Source: Siberian Journal of Clinical and Experimental Medicine; Том 37, № 4 (2022); 63-69 ; Сибирский журнал клинической и экспериментальной медицины; Том 37, № 4 (2022); 63-69 ; 2713-265X ; 2713-2927

    File Description: application/pdf

    Relation: https://www.sibjcem.ru/jour/article/view/1621/759; Beyerstedt S., Casaro E.B., Rangel É.B. COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARSCoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(5):905–919. DOI:10.1007/s10096-020-04138-6.; Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Brüggen M.C. et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564– 1581. DOI:10.1111/all.14364.; Feng Y., Ling Y., Bai T., Xie Y., Huang J., Li J. et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am. J. Respir. Crit. Care Med. 2020;201(11):1380–1388. DOI:10.1164/rccm.202002-0445OC.; Kalyanaraman Marcello R., Dolle J., Grami S., Adule R., Li Z., Tatem K. et al. Characteristics and outcomes of COVID-19 patients in New York City’s public hospital system. PLoS One. 2020;15(12):e0243027. DOI:10.1371/journal.pone.0243027.; Guan W.J., Ni Z.Y., Hu Y., Yu Q., Liu W., Pu J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720. DOI:10.1056/NEJMoa2002032.; Gerayeli F.V., Milne S., Cheung C., Li X., Yang C.W.T., Tam A. et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021;33:100789. DOI:10.1016/j.eclinm.2021.100789.; Wu F., Zhou Y., Wang Z., Xie M., Shi Z., Tang Z. et al. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: A multicenter, retrospective, observational study. J. Thorac. Dis. 2020;12(5):1811–1823. DOI:10.21037/jtd-20-1914.; Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. DOI:10.1001/jama.2020.6775.; Chhiba K.D., Patel G.B., Vu T.H.T., Chen M.M., Guo A., Kudlaty E. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin. Immunol. 2020;146(2):307–314.e4. DOI:10.1016/j.jaci.2020.06.010.; Liu S., Cao Y., Du T., Zhi Y. Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis. J. Allergy Clin. Immunol. Pract. 2021;9(2):693–701. DOI:10.1016/j.jaip.2020.11.054.; Luo J., Chen Y.L., Chen W., Duncan D.A., Hussain H., Sohail B. et al. Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. Allergy Asthma Clin. Immunol. 2021;17(1):67. DOI:10.1186/s13223-021-00569-8.; Beurnier A., Jutant E.M., Jevnikar M., Boucly A., Pichon J., Preda M. et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur. Respir. J. 2020;56(5):2001875. DOI:10.1183/13993003.01875-2020.; Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int. J. Infect. Dis. 2020;94:91–95. DOI:10.1016/j.ijid.2020.03.017.; Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–1062. DOI:10.1016/S0140-6736(20)30566-3.; Müllerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular comorbidity in COPD: Systematic literature review. Chest. 2013;144(4):1163– 1178. DOI:10.1378/chest.12-2847.; Lee H.M., Truong S.T., Wong N.D. Association of adult-onset asthma with specific cardiovascular conditions. Respir. Med. 2012;106(7):948– 953. DOI:10.1016/j.rmed.2012.02.017.; Matsushita K., Ding N., Kou M., Hu X., Zhang L., Huo P. et al. The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. Glob. Heart. 2020;15(1):64. DOI:10.5334/gh.814.; Jacobs M., Van Eeckhoutte H.P., Wijnant S.R.A., Janssens W., Joos G.F., Brusselle G.G. et al. Increased expression of ACE2, the SARSCoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. Eur. Respir. J. 2020;56(2):2002378. DOI:10.1183/13993003.02378-2020.; Peters M.C., Sajuthi S., Deford P., Christenson S., Rios C.L., Montgomery M.T. et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am. J. Respir. Crit. Care Med. 2020;202(1):83–90. DOI:10.1164/rccm.202003-0821OC.; Dahan S., Segal G., Katz I., Hellou T., Tietel M., Bryk G. et al. Ferritin as a marker of severity in COVID-19 patients: A fatal correlation. Isr. Med. Assoc. J. 2020;22(8):494–500.; https://www.sibjcem.ru/jour/article/view/1621

  5. 5
  6. 6
  7. 7
    Academic Journal

    Source: PULMONOLOGIYA; Том 31, № 3 (2021); 304-310 ; Пульмонология; Том 31, № 3 (2021); 304-310 ; 2541-9617 ; 0869-0189

    File Description: application/pdf

    Relation: https://journal.pulmonology.ru/pulm/article/view/2366/1840; Авдеев С.Н., Царева Н.А., Мержоева З.М. и др. Практические рекомендации по кислородотерапии и респираторной поддержке пациентов с COVID-19 на дореанимационном этапе. Пульмонология. 2020; 30 (2): 151–163. DOI:10.18093/0869-0189-2020-30-2-151-163.; World Health Organization. Coronavirus Disease 2019 (COVID-19). Situation Report – 189. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200727-covid-19-sitrep-189.pdf?sfvrsn=b93a6913_2 [Accessed: July 27, 2020].; Министерство здравоохранения Российской Федерации. Временные методические рекомендации: Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 9 (26.10.2020). Доступно на: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062 [Дата обращения: 20.11.20].; Бубнова М.Г., Аронов Д.М. COVID-19 и сердечно-сосудистые заболевания: от эпидемиологии до реабилитации. Пульмонология. 2020; 30 (5): 688–699. DOI:10.18093/0869-0189-2020-30-5-688-699.; Nuche J., Segura de la Cal T., Jiménez López Guarch C. et al. Effect of coronavirus disease 2019 in pulmonary circulation. The particular scenario of precapillary pulmonary hypertension. Diagnostics. 2020; 10 (8): 548. DOI:10.3390/diagnostics10080548.; Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol. 2020; 75 (18): 2352–2371. DOI:10.1016/j.jacc.2020.03.031.; Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiology. 2020; 5 (7): 811–818. DOI:10.1001/jamacardio.2020.1017.; Danzi G.B., Loffi M., Galeazzi G., Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur. Heart J. 2020; 41 (19): 1858. DOI:10.1093/eurheartj/ehaa254.; Magrone T., Magrone M., Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target – a perspective. Endocr. Metab. Immune Disord. Drug Targets. 2020; 20 (6): 807–811. DOI:10.2174/1871530320666200427112902.; Humbert M., Guignabert C., Bonnet S. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J. 2019; 53 (1): 1801887. DOI:10.1183/13993003.01887-2018.; Harder E.M., Small A.M., Fares W.H. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir. Med. 2020; 161: 105850. DOI:10.1016/j.rmed.2019.105850.; Чазова И.Е., Мартынюк Т.В. Клинические рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (II часть). Терапевтический архив. 2016; 88 (10): 63–73. DOI:10.17116/terarkh201688663-73.; Galie N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 2015; 46 (6): 1855–1856. DOI:10.1183/13993003.51032-2015.; Horn E.M., Chakinala M., Oudiz R. et al. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm. Circ. 2020; 10 (2): 2045894020922799. DOI:10.1177/2045894020922799.; Segura de la Cal T., Nuche J., Jiménez López-Guarch C. et al. Unexpected favourable course of Coronavirus Disease 2019 in chronic thromboembolic pulmonary hypertension patients. Arch. Bronconeumol. 2020; 56 (11): 749–752. DOI:10.1016/j.arbres.2020.06.004 (in English, Spanish).; Sardu C., Gambardella J., Morelli M.B. et al. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J. Clin. Med. 2020; 9 (5): 1417. DOI:10.3390/jcm9051417.; Smeda M., Chlopicki S. Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter? Cardiovasc. Res. 2020; 116 (10): e118–121. DOI:10.1093/cvr/cvaa190.; Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. 2020; 41 (19): 1798–1800. DOI:10.1093/eurheartj/ehaa231.; Cooper L.T. Jr. Myocarditis. N. Engl. J. Med. 2009; 360 (15): 1526-1538. DOI:10.1056/NEJMra0800028.; Levy J., Léotard A., Lawrence C. et al. A model for a ventilator-weaning and early rehabilitation unit to deal with post-ICU impairments following severe COVID-19. Ann. Phys. Rehabil. Med. 2020; 63 (4): 376–378. DOI:10.1016/j.rehab.2020.04.002.; Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8 (5): 475–481. DOI:10.1016/S2213-2600(20)30079-5.; Carfì A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324 (6): 603–605. DOI:10.1001/jama.2020.12603.; Mo X., Jian W., Su Z. et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur. Respir. J. 2020; 55 (6): 2001217. DOI:10.1183/13993003.01217-2020.; Patelli G., Paganoni S., Besana F. et al. Preliminary detection of lung hypoperfusion in discharged COVID-19 patients during recovery. Eur. J. Radiol. 2020; 129: 109121. DOI:10.1016/j.ejrad.2020.109121.; Becker R.C. COVID-19 update: COVID-19-associated coagulopathy. J. Thrombosis Thrombolysis. 2020; 50 (1): 54–67. DOI:10.1007/s11239-020-02134-3.; https://journal.pulmonology.ru/pulm/article/view/2366

  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15